Impact of selenium supplementation in neutropenia and immunoglobulin production in childhood cancer patients

Journal of Medicinal Food

Volumn 19, Issue 6, 2016, Pages 560-568

  Rocha, Katya Cristina ^a   Dos Santos Vieira, Maria Luiza ^a   Beltrame, Registila Libania ^a   Cartum, Jairo ^a   Do Alves, Sarah Isabel P M N ^b   Azzalis, Ligia Ajaime ^b   Junqueira, Virginia Berlanga Campos ^b   Pereira, Edimar Cristiano ^b   Fonseca, Fernando Luiz Affonso ^a  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antioxidant activity; ascorbic acid; cancer; dietary supplementation; dietary induced hyperlipidemia; glutathione; malondialdehyde; selenium

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; SELENIUM; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; EOSINOPHIL COUNT; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HISTIOCYTOSIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INFANT; LEUKEMIA; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPENIA; NEUTROPHIL COUNT; NEWBORN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; ANALYSIS; DIETARY SUPPLEMENT; METABOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; NEUTROPENIA; SELENIUM; YOUNG ADULT;

EID: 84974623960     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2015.0145     Document Type: Article

References (57)

1. Cozzolino SMF: Biodisponibilidade de Micronutrientes. Manole, Sao Paulo, 2013.
2. Rayman MP: Selenium and human health. Lancet 2012;379:1256-1268.
3. Terry EM, Diamond AM: Selenium. In: Present Knowledge in Nutrition, 10th Edition ( John W. Erdman Jr, Ian A. Macdonald and Steven H. Zeisel, eds.). International Life Sciences Institute. John Wiley & Sons, Inc., Ames, Iowa, 2012, pp. 568-580.
4. Rayman MP: Selenium in cancer prevention: A review of the evidence and mechanism of action. Proc Nut Soc 2005;64:527-542.
5. Allen NE, Appleby PN, Roddam AW, et al.: Plasma selenium concentration and prostate cancer risk: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr 2008;88:1567-1575.
6. Combs GFJ, Gray WP: Chemopreventive agents: Selenium. Pharmacol Ther 1998;79:179-192.
7. Burk RF: Selenium and cancer: Meaning of serum selenium levels. J Nutr 1986;116:1584-1586.
8. Ockhuizen T, Cardinaals H, Bos P, Veer P: Selenium and prevention of câncer. Voeding 1985;46:416-421.
9. Willett WC, Stampfer MJ: Selenium and cancer. BMJ 1988;297: 573-574.
10. Combs GF Jr, Clark LC: Can dietary selenium modify cancer risk? Nutr Rev 1985;43:325-331.
11. Whanger PD: Selenium and its relationship to cancer: An update. Br J Nutr 2004;9:11-28.
12. Clark LC, Combs GF Jr, Turnbull BW, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial. JAMA 1996;276:1957-1963.
13. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, Horneber M: Selenium for preventing cancer. Cochrane Database Syst Rev 2011:CD005195.
14. Reid ME, Duffield-Lillico AJ, Slate E, et al.: The nutritional prevention of cancer: 400 lg per day selenium treatment. Nutr Cancer 2008;60:155-163.
15. Francesconi KA, Pannier F: Selenium metabolites in urine: A critical overview of past work and current status. Clin Chem 2004;50:2240-2253.
16. Naoum PC: Technological advances in laboratorial haematology. Rev Bras Hematol Hemoter 2001;23:111-119.
17. Volp ACP, Bressan J, Hermsdorff HHM, Zulet MA, Martínez JA: Selenium antioxidant effects and its link with inflammation and metabolic syndrome. Rev Nutr Campinas 2010;23:581-590.
18. Vieira ML, Fonseca FL, Costa LG, et al.: Supplementation with selenium can influence nausea, fatigue, physical, renal, and liver function of children and adolescents with cancer. J Med Food 2015;18:109-117.
19. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G: Regulation of cellular immune responses by selenium. Biol Trace Elem Res 1992;33:23-35.
20. Arthur JR, McKenzie RC, Beckett GJ. Selenium in the immune system. J Nutr 2003;133:1457S-1459S.
21. Radhakrishnan N, Dinand V, Rao S. et al.: Antioxidant levels at diagnosis in childhood acute lymphoblastic leukemia. Indian J Pediatr 2013;80:292-296.
22. Masri DS: Microquantity for macroquality: Case study on the effect of selenium on chronic neutropenia. J Pediatr Hematol Oncol 2011;33:e361-e362.
23. Hoffmann PR, Berry MJ: The influence of selenium on immune responses. Mol Nutr Food Res 2008;52:1273-1280.
24. Boyne R, Arthur JR: The response of selenium-deficient mice to Candida albicans infection. J Nutr 1986;116:816-822.
25. Kukreja R, Khan A: Effect of experimental selenium deficiency and its supplementation on the candidacidal activity of neutrophils in albino rats. Indian J Biochem Biophys 1994;31:427-429.
26. Boyne R, Mann SO, Arthur JR: Effects of Salmonella typhimurium infection on selenium deficient rats. Microbios Lett 1984;27:83-87.
27. Murray JM, Murray AB: The Effects of Selenium Deficiency and Repletion on Host Resistance to Infection. Commonwealth on Agricultural Bureaux, Cambridge, 1985, pp. 244-247.
28. Ongele EA, Ashraf M, Nesbitt RA, Humphrey PA, Lee CM: Effects of selenium deficiency in the development of trypanosomes and humoral immune responses in mice infected with Trypanosoma musculi. Parasitol Res 2002;88:540-545.
29. Boveris A, Sies H, Martino EE, Docampo R, Turrens JF, Stoppani AO: Deficient metabolic utilization of hydrogen peroxide in Trypanosoma cruzi. Biochem J 1980;188:643-648.
30. Institute of Medicine, Food and Nutrition Board: Selenium. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. National Academy Press, Washington, D.C, 2000, pp. 284-324.
31. Carroll L, Pattison DI, Fu S, Schiesser CH, DaviesMJ, Hawkins CL: Reactivity of selenium-containing compounds with myeloperoxidase-derived chlorinating oxidants: Second-order rate constants and implications for biological damage. Free Radic Biol Med 2015;84:279-288.
32. Lee S, Takahashi I, Matsuzaka M, et al.: The relationship between serum selenium concentration and neutrophil function in peripheral blood. Biol Trace Elem Res 2011;144:396-406.
33. Shrimali RK, Irons RD, Carlson BA, et al.: Selenoproteins mediate T cell immunity through an antioxidant mechanism. J Biol Chem 2008;283:20181-20185.
34. Meister A: Glutathione, Ascorbate, and celular protection. Cancer Res 1994;54: 1969S-1975S.
35. Medina MA: Glutamine and cancer. J Nutr 2001;131:2539S-2342S.
36. Klimberg VS, McClellan JL: Glutamine, cancer, and its therapy. Am J Surg 1996;172:418-424.
37. Calabrich AF, Katz A: Iron deficiency in cancer patients. Rev Bras Hematol Hemoter 2010;3295-98.
38. Cançado RD, Chiattone CS: Anemia of chronic disease. Rev Bras Hematol Hemoter 2002;24:127-136.
39. Kaushal N, Hegde S, Lumadue J, Paulson RF, Prabhu KS: The regulation of erythropoiesis by selenium in mice. Antioxid Redox Signal 2011;14:1403-1412.
40. Almondes KG, Leal GV, Cozzolino SM, Philippi ST, Rondó PH: The role of selenoproteins in cancer. Rev Assoc Med Bras 2010; 56:484-488.
41. Pettingale KW, Greer S, Tee DE: Serum IgA and emotional expression in breast cancer patients. J Psychosom Res 1977;21: 395-399.
42. Roberts MM, Bathgate EM, Stevenson A: Serum immunoglobulin levels in patients with breast cancer. Cancer 1975;36:221-224.
43. de Souza RM, Lehn CN, Denardin OV: Serum and salivary immunoglobulin A levels in patients with cancer of the mouth and oropharynx. Rev Assoc Med Bras 2003;49:40-44.
44. Martín Ibáñez I, Arce Casas A, Cruz Martínez O, Estella Aguado J, Martín Mateos MA: Humoral immunity in pediatric patients with acute lymphoblastic leukaemia. Allergol Immunopathol (Madr) 2003;31:303-310.
45. Jensen-Jarolim E, Achatz G, Turner MC, et al.: Oncology: The role of IgE-mediated allergy in cancer. Allergy 2008;63:1255-1266.
46. Matta GM, Battaglio S, Dibello C, et al.: Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. Clin Cancer Res 2007;13:5348-5354.
47. Biggar RJ, Christiansen M, Rostgaard K, et al.: Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma. Int J Cancer 2009;124:2616-2620.
48. Lindelof B, Granath F, Tengvall-Linder M, Ekbom A: Allergy and cancer. Allergy 2005;60:1116-1120.
49. Gandini S, Lowenfels AB, Jaffee EM, Armstrong TD, Maisonneuve P: Allergies and the risk of pancreatic cancer: A metaanalysis with review of epidemiology and biological mechanisms. Cancer Epidemiol Biomarker Prev 2005;14:1908-1916.
50. Linos E, Raine T, Alonso A, Michaud D: Atopy and risk of brain tumors: A meta-Analysis. J Natl Cancer Inst 2007;99:1544-1550.
51. Rosenbaum PF, Buck GM, Brecher ML: Allergy and infectious disease histories and the risk of childhood acute lymphoblastic leukaemia. Paediatr Perinat Epidemiol 2005;19:152-164.
52. Schuz J, Morgan G, Bohler E, Kaatsch P, Michaelis J: Atopic disease and childhood acute lymphoblastic leukemia. Int J Cancer 2003;105:255-260.
53. Wen W, Shu XO, Linet MS, et al.: Allergic disorders and the risk of childhood acute lymphoblastic leukemia (United States). Cancer Causes Control 2000;11:303-307.
54. Fu SL, Pierre J, Smith-Norowitz TA, et al.: Immunoglobulin E antibodies from pancreatic cancer patients mediate antibodydependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008;153:401-409.
55. Pellegrino MG, Bluth MH, Smith-Norowitz T, et al.: HIV type 1-specific IgE in serum of long-Term surviving children inhibitsHIV type 1 productionin vitro. AIDS Res Hum Retroviruses 2002 18:363-372.
56. Karagiannis SN, Bracher MG, Hunt J, et al.: E-Antibody-dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007;179: 2832-2843.
57. Karagiannis SN, Wang Q, East N, et al.: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003;33:1030-1040.